Alkylating agents can be administered in high dosage to patients with ovarian cancer using autologous bone marrow support, but drug-resistant tumor cells can still persist. Immunotoxins provide reagents that might eliminate drug resistant cells. In the present study, concurrent treatment with alkylators and immunotoxins proved superior to treatment with each agent alone. Toxin immunoconjugates prepared from different monoclonal antibodies and recombinant ricin A chain (rRTA) inhibited clonogenic growth of ovarian cancer cell lines in limiting dilution assays. When alkylating agents and toxin conjugates were used in combination, the addition of the immunotoxins to cisplatin, or to cisplatin and thiotepa, produced synergistic cytotoxic activity against the OVCA 432 and OVCAR III cell lines.
Introduction
Most ovarian cancer is diagnosed in advanced stage and, therefore, cannot be cured by surgery. Thus, after excision of as much tumor as possible, ovarian cancer patients are treated aggressively with platinum-based combination chemotherapy. Most patients respond to cytotoxic chemotherapy and many appear to be cured on clinical evaluation. Unfortunately, a majority ofthese patients will develop recurrent disease refractory to other available therapy. This is felt to result from the regrowth of drug resistant tumor cells. Thus, there is a major need to find approaches to prevent or reverse drug resistance when it occurs.
Immunotoxins are anticancer agents produced by conjugation ofan antibody and a toxin. The antibody permits selective targeting ofthe toxin to tumor cells (1) . Since the mechanisms by which immunotoxins exert their cytotoxic effects differ from those ofalkylating agents including platinum drugs, toxin immunoconjugates could potentially eliminate alkylator resistant cells. Moreover, the concurrent use of alkylators and immunotoxins in combination might prove superior to treatment with the individual agents alone.
In a previous study, serial dilution clonogenic assays were used to evaluate the impact of alkylating agents on growth of established ovarian cancer cell lines (2) . Isobolographic analysis showed that the combinations of cisplatin together with thiotepa, melphalan, or 4-hydroxyperoxy-cyclophosphamide exerted synergistic cytotoxic activity against the OVCA 432, 420, 429, and 433 cell lines. Other studies have shown that immunotoxins exert cytotoxic and antitumor effects against ovarian cancer cell lines and heterografts (3, 4) . The effects of concurrent treatment of ovarian cancer cells with immunotoxins and alkylators has not, however, been previously described.
In the present study, we have shown that immunotoxins prepared from two distinct monoclonal antibodies and recombinant ricin A chain (rRTA) 1 (5) . OVCAR III was purchased from American Type Culture Collection (Rockville, MD) (6) . Cells were maintained in Eagle's minimum essential medium with Earle's salts (OVCA 432), or RPMI 1640 (OVCAR III), supplemented with 10% heat inactivated FBS, 1 mM L-glutamine, 1 mM sodium pyruvate, nonessential amino acids (0.1 mM each), 100 ,g/ml streptomycin, and 100 U/ml penicillin (tissue culture media [TCM] ). Unless otherwise indicated, cells were trypsinized before the experiments and aliquoted in 5-ml polypropylene tubes. Trypsinized cells were treated with drugs or immunotoxin at 370C in an atmosphere of 5% CO2 and 95% humidified air for 3 h on a rocking platform.
Drugs and immunoconjugates
Cisplatin (cis-diamminedichloro-platinum [II]) (Bristol-Myers Co., New York) was stored at room temperature, and thiotepa (tri-methyleneiminethiophosphoramide) (Lederle Laboratories, Pearl River, NY) was stored at 4VC. Alkylating agents were dissolved in H20 immediately before use and diluted to appropriate concentrations in TCM. rRTA was generously provided by Cetus Corp., Emeryville, CA. The 317G5 murine monoclonal antibodies were obtained as described (7) . The BT 1 IA9. 13 antibody was prepared in ourlaboratory after immunization of mice with BT20 breast cancer cells. Both 317G5 and BTl 1A9.13 bind to a 42-43-kD glycoprotein on the cell surface of human breast and ovarian cancer cells (8) . The preparation of the rRTA conjugates was previously described (9) .
Serial dilution clonogenic assay and isobolographic analysis Drug cytotoxicity was evaluated using a limiting dilution technique as described previously ( 10) . Briefly, after trypsinization, 106 tumor cells were incubated with drugs and/or immunotoxins in a total volume of 1 ml. Cells were then washed twice with TCM. A series of nine fivefold dilutions was prepared. Six aliquots ( 100 Ml) of each dilution were plated in 96-well flat-bottomed microtiter plates that had been preloaded with 100 ,l TCM. Plates were incubated for 14 d at 37°C in 5% CO2 and 95% humidified air. Growth ofcolonies (> 50 cells) was evaluated by visual scoring (2) . Each value was calculated from a mean of duplicate plates. Limiting-dilution analysis was performed as described (10) .
Isobolographic analysis, a geometric method to explore drug interactions, was performed as described by Berenbaum (1 1, 12) and Steel and Peckham (13) . Isoboles for different levels of cytotoxicity were drawn from dose-response curves, in which the log effect by dose ofone agent was plotted for each constant dose of the other agents in the combination. The calculation of an "envelope of additivity" between modes I and II, which indicated the theoretical limits of the additive effects obtained from an interaction of two agents, is described elsewhere (2, 13 ).
An interaction between three agents was considered to be synergistic when the combined cytotoxic effects exerted by the three different agents created a concave isobolar surface (the surface joining all the dose combinations producing a given quantitative effect). According to Berenbaum ( 1 1), the interaction between three agents could be generalized using the iso-effective dose fraction formula: Internalization of31 7G5-rRTA into drug-treated cells The 317G5-rRTA conjugate was labeled with Na 125I using the iodogen method ( 14) . Internalization was measured as previously described (15) . Briefly, radioiodinated 317G5-rRTA (I g/ml) was incubated with drug-treated OVCA 432 cells (5 X 105) at 4VC for 1 h. After removal of excess conjugate with cold culture medium containing 1% BSA, the cells were incubated either at 40C or 370C for a period of 4 h, and then treated with proteinase K ( 100 Ml of2.5 mg/ml solution) for 1 h at 370C with gentle shaking. Cells were then washed three times with cold medium containing 1% BSA and 0.1% NaN3. Radioactivity was measured in a gamma counter (Packard Instruments (Meriden, CT).
Uptake of Il9'm]Pt-cisplatin (84 ACi/mmol) was obtained from Oak Ridge National Laboratories (Oak, Ridge, TN). Cell size was determined with a Coulter electronic particle counter equipped with a channel analyzer (models ZB and C1000; Coulter Electronics, Hialeah, FL).
The uptake of 19smlPt-cisplatin was determined as described before (16) with minor variations. Briefly, 2 X 106 OVCA 432 cells were incubated in 5-ml polypropylene tubes with different concentrations of 1'95mlPt-cisplatin (10-100 Mmol) for 0.5-30 min, in a volume of 1 ml TCM at 37-C. A 600-Al aliquot ofeach sample was then diluted 10-fold with ice-cold 0.9% NaCl, and cells were centrifuged at 500 g for 5 min at4C. The pellet was washed twice with ice-cold 0.9% NaCl and solubilized overnight at 37°C in Aquasol-2 (New England Nuclear Research Products, Boston, MA). Radioactivity was measured in a scintillation counter (Tri-carb 4640). Uptake velocity was calculated from the linear portion ofa curve after correction for the initial rapid binding ofthe drug. The reciprocal velocities were plotted against the reciprocal ['9'm]Pt-cisplatin concentrations. The resulting Lineweaver-Burk plots were analyzed by linear regression and the Km and V. of each treatment modality were determined from the slopes and intercepts ofthese plots. Data were also analyzed for two-component transport without correction for the initial rapid binding of the drug according to the formula of Neal ( 17) .
Intracellular levels ofglutathione (GSH)
Cells (2-5 X 106; 60% confluent) were lysed by sonication in 1 ml of PBS at 4°C. The supernatant was obtained for assay after centrifugation (10,000 g, 10 min, 40C). The protein was precipitated by adding 12% 5-sulfosalicylic acid (SSA) (1 vol SSA to 3 vol of sample). After standing on ice for 1-4 h, the samples were centrifuged (10,000 g, 10 min). The SSA extract was assayed as described by Tietze ( 18) and modified by Griffith ( 19, 20) , using 100 ,l of sample and 0.5 U of glutathione reductase per assay. Protein in the PBS lysate was determined by the Lowry assay (21) (Bio-Rad Laboratories, Richmond, CA) using bovine serum albumin as standard.
Intracellular activity ofglutathione-S-transferase (GST)
Activity was measured with l-chloro-2,3-dinitrobenzene (22) . The PBS extract (above) was used after centrifugation. The reaction mixture contained glutathione (1 mM), l-chloro-2,3-dinitrobenzene (1 mM), and sample (100 ,uM) in a final volume of 1 ml. The rate of increase in absorbance at 340 nm was measured at 250C. 
Results
Synergistic interaction between immunotoxin and cisplatin. Using serial dilution clonogenic assays of OVCA432 growth, dose response curves were generated for the cytotoxic effects of cisplatin, thiotepa, and 317G5-rRTA, alone and in combination. Three-dimensional isobolographic analysis was then performed. Isoboles for 1.5, 2, 3, and 4 log-reduction ofclonogenic cell growth are plotted in Fig. 1, a- (2, 28) . In the present study, using a combination ofcisplatin and 31 7G5-rRTA, we obtained synergistic cytotoxic activity against OVCAR III (Fig. 2) . Thus, supra-additive cytotoxicity could be obtained against cisplatin resistant or cisplatin sensitive ovarian cancer cells when an immunotoxin was Modes I and II enclose an envelope of additivity for 1.5 log reduction of clonogenic cell growth. The isobole ofthe combined effect is mostly supra-additive, since it falls below the envelope of additivity.
added to cisplatin alone or to a combination of cisplatin and thiotepa. The synergistic effect against OVCAR III was maintained when 31 7G5-rRTA was replaced with BT 1 1A9. 1 3-rRTA (Fig.  3 ). 317G5 and BT1 IA9. 13 recognize different epitopes on the same 42-kD cell surface glycoprotein expressed by human breast and ovarian cancer cells.
Internalization of3J 7G5-rRTA into drug-treated cells. One important determinant of the cytotoxic activity exerted by ricin A chain on malignant cells is the rate at which bound immunotoxin is internalized into the cytoplasmic compartment. The conjugate is transported into receptosomes through clathrin-coated pits in a process that might be influenced by treatment with alkylators, since alkylating agents have been shown to inhibit uptake of amino acids through the ASC carrier system (16), as well as to damage cell membranes (29). (31) . Depletion of intracellular GSH renders cells more radiosensitive (28) , and elevated GSH levels result in radioprotection and decreased sensitivity to many anticancer drugs (32) . To study the role played by glutathione in the interaction between 31 7G5-rRTA and alkylating agents, we measured the intracellular concentration ofGSH after treatment of OVCA 432 cells with diluent, alkylating agents, or immunotoxins. Glutathione levels in cells treated with a combination of cisplatin, thiotepa, and 31 7G5-rRTA were lower than the levels found in the diluent treated cells or in cells treated with cisplatin alone (Table  II) . The observed GSH depletion was statistically significant and reproducible (Student's t test and ANOVA P < 0.003). Intracellular levels of GSH also decreased somewhat after treatment with the immunotoxin and either single alkylating agent, but the decrease was not statistically significant. Intracellular activity ofGST. Glutathione S-transferase catalyzes reactions in which GSH, as a nucleophile, can bind to compounds bearing electrophilic atoms (33). As a result, the GST group ofenzymes takes part in the detoxification ofalkylating agents, converting them to less active compounds (22, 34) . The intracellular activity of GST was measured in OVCA 432 cells treated with alkylating agents and 31 7G5-rRTA. Glutathione S-transferase activity in cells treated with the combinations of cisplatin, thiotepa, and 317G5-rRTA was lower than the activity found in untreated cells and in those treated with the alkylators alone. A reduction of 22% was observed in cells treated with the three agents together as compared to the activity ofGST found in the cells treated with cisplatin alone ( Table   Table II with 317G5-rRTA in addition to the alkylators (P < 0.004, ANOVA P < 0.001). Discussion III). This reduction was highly significant (Student's t test P < 0.006 and ANOVA P < 0.008).
Adduct formation. Intrastrand, interstrand, and DNA-Ptprotein adducts are formed when cisplatin binds covalently to DNA. Intrastrand adducts are observed most frequently and exhibit sequence-specific binding of cisplatin to DNA forming bidentate N7-deoxy (G-Pt-G) linkages between adjacent bases on the same strand. Interstrand DNA-Pt adducts are composed of cisplatin bound to two guanines on opposite DNA strands, perturbing G-C base pairing, leading to unwinding and shortening of DNA (35) (36) (37) . CDDP-DNA adduct formation in OVCA 432 cells was studied after incubation with "'95m]Ptcisplatin. OVCA 432 cells were treated for 1 h with thiotepa, 317G5-rRTA, neither, or both agents. Cells were then incubated for 1 h with or without '9smlPt-cisplatin. The concentration of cisplatin-DNA adducts in cells treated with a combination of cisplatin, thiotepa, and 317G5-rRTA was about twice that found in the cells treated with the alkylators (Student's t test P < 0.017 and ANOVA P < 0.008) (Fig. 5) . A significant increase in adduct formation was also observed in cells treated with a combination of cisplatin and 31 7G5-rRTA, when compared to adducts formed in cells treated with alkylators alone (P<0.03).
DNA repair. DNA repair after alkylator damage can play a major role in acquired resistance to cisplatin (38) . The most general repair mechanism known is nucleotide excision that removes ultraviolet-induced lesions and chemical adducts from damaged DNA (39) . Excision repair of total cellular DNA was evaluated in OVCA 432 cells by measuring unscheduled DNA synthesis following alkylator damage. When compared to diluent treated cells, bulk repair activity was substantially increased in cells treated with cisplatin (Fig. 6) . When compared to levels of repair observed after treatment with cisplatin alone or in combination with thiotepa, a significant reduction of bulk repair activity was observed in cells treated Approximately 60-75% of ovarian cancer patients are diagnosed initially with advanced stage disease (40) . Alkylating agents have proven beneficial in the treatment of these patients (41, 42) , but most often only temporary remissions are achieved with platinum-based combination chemotherapy. Thus, the long term survival of ovarian cancer patients with bulky disease has only slightly improved during the last two decades (43) (44) (45) . It is generally accepted that the emergence of drug resistance is the cause for treatment failure (46, 47) . If In several preclinical studies, resistance to cisplatin in ovarian cancer has been associated with increased cellular levels of GSH, increased activity of GST, and increased DNA repair of drug induced damage (48 (52) . GSH depletion may also inhibit normal and activated lymphocytic proliferative response (53, 54) . Aphidicolin may induce breaks at fragile sites on human chromosomes and telomere association in normal cells (55, 56) .
In the present study, we have demonstrated that immunotoxins modulate sensitivity of ovarian cancer cells to alkylators. In contrast to chemosensitizers such as BSO and aphidicolin, immunotoxins have strong cytotoxic activity and this activity is produced by mechanisms distinct from alkylating agents. Thus, these agents may produce efficacy in two ways. First, by direct action, and second, like BSO and aphidicolin, immunotoxins may inhibit enzymes required for the prevention and repair ofalkylator damage. In a previous study, nontoxic doses of BSO decreased GSH levels in ovarian cancer cells to 20% of control, potentiating cytotoxicity of alkylators in OVCA cells, and reversing completely resistance to melphalan in the 1847ME OVCA cell line (57) . In the present study, GSH depletion ofup to 16.4% ofcontrols was obtained with combinations of 317G5-rRTA and cisplatin, and synergistic modulation of cisplatin resistance in the OVCAR III cell line was observed.
Several enzymes take part in drug detoxification and in the removal of drug-induced free radicals by GSH (including gamma-glutamyl cysteine synthetase, glutathione reductase, and glutathione peroxidase). The effect of immunotoxins on enzymes other than GST remain to be explored, but based on the mechanism ofaction ofricin, indirect effects might be anticipated. Ricin toxin inactivates protein synthesis at the translational stage, by depurinatation of a single adenine base at the 28S rRNA of the 60S ribosomal subunit, near the elongation factor 2 binding site (58, 59). Unlike BSO or aphidicolin, specific inhibition of enzymes by ricin toxin has not been previously demonstrated. Thus, reduction of level or activity of enzymes participating in intracellular thiol and DNA repair pathways is most likely secondary to the general arrest of protein synthesis induced by the immunotoxin. Moreover, depletion of intracellular glutathione could account, at least in part, for the modulation of DNA repair observed in the present study (25) . Selective sensitization of tumor cells to alkylator damage could provide an additional therapeutic advantage, particularly in the setting of high dose therapy with autologous bone marrow support, where appropriate concentration of alkylating agents can be achieved in vivo. In this setting, immunotoxins might be given on a single occasion obviating the effects of human antiovarian antibodies that arise after repeated injections of murine immunoglobulins. The specificity of the immunotoxin will also be important. The 317G5 antibody binds to a 42-43-kD protein that can be found in a majority of ovarian and breast cancers, as well as the normal epithelium of the intestine and renal collecting tubules. Whether this specificity will permit effective use of 31 7G5 in clinical trials remains to be determined, but the principle ofsynergistic interactions may apply to reagents with many different specificities.
